No Data
No Data
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
wuxi apptec received the "Gold" certification for corporate social responsibility rating from EcoVadis in 2024.
Wuxi Apptec recently announced that the company received gold certification in the 2024 EcoVadis corporate social responsibility rating, ranking in the top 2% of all participating companies.
Right For Malaysia's Energy Transition To Include Nuclear
Open Source Securities' investment strategy for the pharmaceutical industry in 2025: The long-term industry trend has not changed, focusing on the sector stabilizing and rebounding.
At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, and the continuous improvement of enterprise innovation capabilities are long-term industry trends that have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance income suppressing the pharmaceutical sector will gradually improve.
Wuxi Apptec responds to "Evolution of Laws after Trump Takes Office": Currently no direct impact | Directly addressing the earnings conference
①The US presidential election does not have a direct impact on the ongoing legislative process of the biosafety law; ②In response to the uncertainty brought by Xavier Becerra's appointment as the US HHS Secretary, Wuxi AppTec emphasizes that "customer demands for cost, efficiency, and quality will not change"; ③As of the end of September, Wuxi AppTec's hand order is 43.82 billion yuan, a year-on-year increase of 35.2%.
Wuxi Apptec (603259.SH): Intends to subscribe for 10 million euros of private equity fund shares.
Gelonghui November 15th | wuxi apptec (603259.SH) announced that its wholly-owned subsidiary WuXiPharmaTechHealthcareFundIL.P. (referred to as "WuXiFundI") signed a SubscriptionAgreement with SofinnovaCapitalXIGPS.àr.l. (referred to as "general partner"), agreeing that WuXiFundI will subscribe to SofinnovaCapitalXISCSpSICAV-